Biosimilars 2017 Global Market Expected to Grow at CAGR of 55.52% and Forecast to 2021

Wiseguyreports.Com Publish New Market Research Report On-“Biosimilars 2017 Global Market Expected to Grow at CAGR of 55.52% and Forecast to 2021”.

PUNE, INDIA, October 6, 2017 /EINPresswire.com/ --

Biosimilars Market 2017

Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator’s product. They have many similarities, but are not identical to, the reference biopharmaceutical product.

The analysts forecast the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global biosimilars market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products such as somatropin, erythropoietin, colony-stimulating factors (CSF), interferons, interleukins, insulin and insulin analogs, follicle stimulating hormones (FSH), monoclonal antibodies (mAbs), and low molecular weight heparins (LMWH).

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA


Request a Sample Report @ https://www.wiseguyreports.com/sample-request/592563-global-biosimilars-market-2016-2020


The report, Global Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Biocon
• Celltrion
• Dr. Reddy's Laboratories
• Hospira
• Sandoz
• STADA
• Teva Pharmaceuticals

Other prominent vendors
• 3SBio
• Accord Healthcare
• AET Biotech
• Allergan
• Alvartis Pharma
• Amega Biotech
• Amgen
• Apotex
• Aspen
• AstraZeneca
• Aurobindo Pharma
• Baxter
• Bharat Serums
• Bio Sidus
• Biogen
• Bionovis
• Bioton
• BioXpress Therapeutics
• Boehringer Ingelheim
• Boston Oncology
• Cipla
• Coherus Biosciences
• Daiichi Sankyo
• Emcure Pharmaceuticals
• Gedeon Richter
• GeneScience Pharmaceuticals
• GSK

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


Any Query, Submit Here @ https://www.wiseguyreports.com/enquiry/592563-global-biosimilars-market-2016-2020


Table of Contents –Analysis of Key Points

PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by application
• Global blood disorders biosimilars market
• Global oncology biosimilars market
• Global chronic and autoimmune diseases biosimilars market
• Global growth hormone deficiency biosimilars market
• Global infectious diseases biosimilars market

PART 08: Market segmentation by end-user
• Hospitals
• Retail pharmacies

PART 09: Geographical segmentation
PART 10: Market drivers
• Rise in number of patent expiries
• Need for cost-effective treatment
• Reimbursement benefits for biosimilars
• Favorable government regulations
• Promising pipeline

PART 11: Impact of drivers
PART 12: Market challenges
• Physicians reluctance to prescribe biosimilars
• Multiple manufacturing complexities
• Risks related to drug failure
• Limited availability of biosimilar products
• Difficulties in patient recruitment for conducting clinical trials

PART 13: Impact of drivers and challenges
PART 14: Market trends
• Emergence of biosimilars
• Outsourcing of biosimilar manufacturing activities
• Need for high investment in R&D
• High growth in the emerging markets
• Rising number of strategic collaborations
..…..Continued

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here